Tunisia's Central Pharmacy in critical state, says MP, raising concerns about drug availability
Tunisia's drug crisis has reached a new alert level, with MP Bouthayna Ghanemi stating on August 8, 2026, that the Central Pharmacy is in a "state of clinical death." Ghanemi highlighted the pharmacy's fragile position as the sole supplier for public hospitals, citing accumulated debts and procurement difficulties. This has severely reduced its storage and distribution capacity, with current drug stocks estimated to last only two weeks, down from a previous six months. This situation threatens the continuity of treatments, particularly for patients with chronic illnesses who require regular medication. This warning follows a statement on August 4 from 17 Members of Parliament, who addressed the revision of drug prices. These MPs cautioned that the crisis extends beyond pricing, stemming from deeper imbalances in funding, governance, sector relations, public institutions, and social security funds. They also expressed concern about the social impact of price increases, emphasizing that patients should not bear the brunt of the system's financial and organizational challenges, and that medication is fundamental to healthcare rights and health security.
